Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 30 Jun 22 424B5 Prospectus supplement for primary offering
- 6 May 22 EFFECT Notice of effectiveness
- 4 May 22 POS AM Prospectus update (post-effective amendment)
- 1 Mar 22 POS AM Prospectus update (post-effective amendment)
-
1 Mar 22 POSASR Automatic shelf registration (post-effective amendment)
- 21 May 21 424B5 Prospectus supplement for primary offering
- 17 Aug 20 FWP Free writing prospectus
- 14 Aug 20 424B5 Prospectus supplement for primary offering
- 13 Aug 20 FWP Free writing prospectus
- 13 Aug 20 FWP Free writing prospectus
- 11 Aug 20 424B5 Prospectus supplement for primary offering
- 11 Aug 20 S-3ASR Automatic shelf registration
Filing view
External links
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in this Registration Statement on Form S-3 of Seres Therapeutics, Inc. of our report dated March 2, 2021 relating to the financial statements, which appears in Seres Therapeutics, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2020. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ PricewaterhouseCoopers LLP Boston, Massachusetts March 1, 2022 |